Clean Watchlist Candidate
JUXTAPID
JUXTAPID carries use-code patent, low complexity (1/5), and meaningful clinical competition (3/5). The listed expiry window is approximately 13 months away. Active clinical competition may compress the generic entry window.
LOE window
13months
to latest listed patent expiry (August 19, 2027)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (none)
Use-code patent (listed)
Patent count: 1
Complexity score: 1/5
Clinical competition
Score: 3/5
Active trials linked: 21
Phase 2/3 trials: 12
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: LOMITAPIDE MESYLATE
Applicant (NDA holder): CHIESI FARMACEUTICI SPA
Confidence: Medium